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Abstract
Background: Ligand-targeted approaches have proven successful in improving the therapeutic index of a number
of drugs. We hypothesized that the specific targeting of TNF-alpha antagonists to inflamed tissues could increase
drug efficacy and reduce side effects.
Results: Using uteroglobin (UG), a potent anti-inflammatory protein, as a scaffold, we prepared a bispecific
tetravalent molecule consisting of the extracellular ligand-binding portion of the human TNF-alpha receptor P75
(TNFRII) and the scFv L19. L19 binds to the ED-B containing fibronectin isoform (B-FN), which is expressed only
during angiogenesis processes and during tissue remodeling. B-FN has also been demonstrated in the pannus in
rheumatoid arthritis. L19-UG-TNFRII is a stable, soluble homodimeric protein that maintains the activities of both
moieties: the immuno-reactivity of L19 and the capability of TNFRII to inhibit TNF-alpha. In vivo bio-distribution
studies demonstrated that the molecule selectively accumulated on B-FN containing tissues, showing a very fast
clearance from the blood but a very long residence time on B-FN containing tissues. Despite the very fast
clearance from the blood, this fusion protein was able to significantly improve the severe symptomatology of
arthritis in collagen antibody-induced arthritis (CAIA) mouse model.
Conclusions: The recombinant protein described here, able to selectively deliver the TNF-alpha antagonist TNFRII
to inflamed tissues, could yield important contributions for the therapy of degenerative inflammatory diseases.
Background
One of the key inflammatory mediators in chronic
inflammatory processes is the cytokine tumour necrosis
factor-alpha (TNF-alpha). In fact, it has been demon-
strated that TNF-alpha plays a role in various inflamma-
tory diseases such as rheumatoid arthritis (RA),
ankylosing spondylitis, psoriasis, Crohn’s disease, psoria-
tic arthritis, and juvenile idiopathic arthritis [1]. This
observation led to the generation of TNF-alpha antago-
nists such as Infliximab (trade name REMICADE) a
mouse-human chimeric monoclonal, etanercept (trade
name ENBREL) a TNF-alpha receptor p75-IgG fusion
protein and adalimumab (trade name HUMIRA) a fully
human IgG1 monoclonal antibody. Each of these three
antagonists binds to TNF-alpha, thereby preventing it
from activating its receptor. The use of these TNF-alpha
inhibitors has led to dramatic clinical improvements in
the treatment of the above-mentioned diseases [[1,2]
and references therein]].
The major therapeutic goal when administering TNF-
alpha inhibitors is to neutralize the surplus of TNF-
alpha both from the blood circulation and from
inflamed tissues. In RA higher than normal TNF levels
have been detected in both serum and arthritic joints. In
Crohn’s disease TNF concentration is abnormally high
i ns e r u ma sw e l la si nt h eg u tm u c o s a .I np s o r i a s i se l e -
vated TNF levels have been measured in serum and in
the epidermis of psoriatic plaques [[1,2] and references
therein]. While TNF-alpha present in the bloodstream
can be annulled without particular problems, its neutra-
lization in inflamed tissues requires the effective pene-
tration and an optimal concentration of the drug in the
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any medium, provided the original work is properly cited.diseased tissues. To achieve this high doses of the TNF-
alpha inhibitor would be needed, but these would be
accompanied by severe side effects [3]. A possible solu-
tion to this problem is the generation of small molecules
with enhanced penetration into tissues. Neve et al. first
investigated this possibility in 1994 by substituting the
Fc portion of IgG present in Etanercept with a smaller
linker[4]. However the fast blood clearance of a small
molecule is very likely to reduce its therapeutic
performance.
Another attractive possibility is the targeted delivery of
the TNF-alpha antagonist directly to inflamed tissues by
fusing the agents with a ligand that can to selectively
transfer the drug to a specific target. A long residence
time of the drug in the target should overcome the pro-
blems caused by the fast blood clearance. The selection
of the target is crucial for this kind of system. A recent
paper describes an elegant approach of targeting
arthritic cartilage using an scFv specific for ROS (reac-
tive oxygen species) modified collagen II. In fact there is
an excessive level of ROS in RA. Using a fusion protein
constituted by the scFv to ROS-modified collagen II and
TNFRII they report that it significantly reduced inflam-
mation in arthritic mice compared to the TNF-RII-Fc
alone [5].
As a target we chose B-FN, a fibronectin (FN) isoform
containing the extra-domain B (ED-B), is undetectable
in the tissues of healthy adults. By contrast, it is signifi-
cantly up regulated in foetal and tumour tissues and all
angiogenesis-associated diseases including inflammatory
degenerative pathologies [6-8]. In RA B-FN has been
demonstrated in the pannus [9]. The pannus is a highly
vascularised inflammatory granulation tissue that
spreads from the synovial membrane and invades the
joints. Furthermore, B-FN has been associated with the
invasive phenotype described in RA. Previous studies
have demonstrated that a fusion protein composed of
IL10 and the anti-ED-B scFv L19 selectively accumulates
in the RA-affected joints in a mouse experimental model
[10,11]. More recently, it has been demonstrated that a
human recombinant antibody to B-FN, conjugated to a
near infrared dye, selectively accumulates in the
inflamed joints of the collagen antibody-induced arthri-
tis (CAIA) mouse model, which enables fluorescence
imaging of RA affected joints in vivo [12].
These observations have prompted our investigation
into approaches that allow the selective delivery of
TNF-alpha antagonists to RA-affected joints. We gener-
ated a tetravalent dual specific fusion protein composed
of the active moiety of Etanercept, TNFRII, and the scFv
L19, a human scFv to ED-B which is currently used
extensively in preclinical studies as well clinical trials to
target B-FN in different kind of cancers [13,14]. To con-
struct the L19-TNFRII fusion protein we used
uteroglobin (UG), a small (15.8 kDa), globular, non-gly-
cosilated and homodimeric protein [15], as a scaffold.
We have previously reported that the use of UG as a
scaffold improves properties of solubility and stability of
recombinant fusion proteins. In addition, since UG gen-
erates a covalently linked homodimer, we demonstrated
that it is possible to generate dual specific tetravalent
molecules using a single cDNA construct [15,16]. Using
UG as a linker, different kinds of fusion proteins have
been generated that, compared to similar fusion proteins
without UG, possess enhanced properties of solubility
and stability, factors that expedite their storage and clin-
ical uses. Moreover, UG contains a central hydrophobic
c a v i t ya b l et oa c c o m m o d a t eh y d r o p h o b i cm o l e c u l e s
such as progesterone, retinol and prostaglandin D2.
Theoretically this cavity could be loaded with different
types of therapeutic substances and delivered to the tar-
get. Furthermore, the use of UG as a scaffold is not only
a flexible and robust procedure for the generation of
dual specific tetravalent fusion proteins, but, given the
potent anti-inflammatory properties of UG, it is the lin-
ker of choice for the generation of fusion proteins for
therapeutic uses in inflammatory diseases [13]. In fact,
UG has been demonstrated capable of inhibiting the
secretory phosholipase A2, a key enzyme in the produc-
tion of diverse mediators of inflammation that plays a
crucial role in inflammatory diseases like RA [15,17]. A
synthetic peptides called Antiflammin, derived from UG,
is one of the most potent anti-inflammatory agents and
has been used to generate powerful anti-inflammatory
molecules [18-21]. Furthermore, UG can modulate tis-
sue transglutaminase. In fact, in an experimental model
of crescentic glomerulonepritis, UG was able to attenu-
ate renal inflammation by modulating the expression of
tissue transglutaminase [22,23].
This paper reports on the production and characteri-
zation of the fusion protein L19-UG-TNFRII and its
ability to selectively accumulate in vivo in B-FN-contain-
ing tissues and to significantly improve the objective
signs of arthritis in the in CAIA mouse model.
Results
Expression, Purification And Characterization of L19-UG-
TNFRII Fusion Protein
We generated a dual specificity tetravalent molecule,
L19-UG-TNFRII, using human UG to link the extracel-
lular ligand-binding portion of the human TNF-alpha
receptor 75 (p75) (TNFRII) with the scFv L19 specific
for the ED-B domain of FN (Figure 1B). We appended
the cDNA of the scFv L19 and the cDNA of TNFRII at
the 5’ and 3’ends of the UG cDNA, respectively (Figure
1A). The construct was inserted into a mammalian
expression vector and used to transfect CHO cells. The
fusion protein was purified from the conditioned media
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described in “Methods”.
The purified fusion protein was then analyzed in SDS-
PAGE (Figure 1C) in which it migrated as a monomer
of the expected size of about 60 KDa in reducing condi-
tions, while it migrated as a homodimer with an appar-
ent molecular mass of about 120 kDa under non-
reducing conditions. The size exclusion chromatography
profile (Superdex 200) showed a single peak with a
retention volume corresponding to the apparent mole-
cular mass of the homodimer and the absence of any
aggregate (Figure 1D).
The purified fusion protein was tested for immunoreac-
tivity of the scFv moiety by immunohistochemistry and
ELISA and the same immunoreactivity of the original scFv
was found (data not shown). L19-UG-TNFRII was also
evaluated for the biological activity of the TNFRII
components by measuring its ability to inhibit TNF-alpha
using a cytotoxic assay on LM mouse fibroblasts. As
shown in Figure 2A the TNF-alpha neutralizing capabil-
ities of TNFRII were preserved in the fusion protein,
thereby demonstrating that the scFv L19 and TNFRII
within the fusion protein do not interfere with each other.
To demonstrate that L19-UG-TNFRII inhibits TNF-
alpha activity even when it is bound to ED-B, we
mimicked the targeted delivery of L19-UG-TNFRII to
tissues containing B-FN, running citotoxicity experi-
ments on LM cells seeded on plates pre-coated with the
FN recombinant fragment 7.ED-B.8.9. After incubating
the cells with L19-UG-TNFRII and washing out the
excess, TNF-alpha was added. Under this condition only
the L19-UG-TNFRII bound to the B-FN recombinant
fragment is present on the plates. The results, shown in
Figure 2B, demonstrated that even when L19-UG-
Figure 1 L19-hUG-TNFRII characterization. A) Scheme of the cDNA of L19-UG-TNFRII including the leader peptide; CMV cytomegalovirus
promoter. B) Schematic representation of homodimeric L19-UG-TNFRII. C) SDS-PAGE analysis of purified L19-UG-TNFRII under reducing (R) and
non-reducing (NR) conditions; on the left the molecular masses of the standards in kDa. D) Size exclusion chromatography profile (Superdex 200)
of purified L19-UG-TNFRII; mAU, milli-absorbance units.
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able to neutralize TNF-alpha cytotoxicity. On the con-
trary when L19-UG-TNFRII was premixed with a large
excess of recombinant ED-B to neutralize the L19 moi-
ety of the fusion protein, no inhibition of the cytotoxi-
city activity of TNF-alpha was observed (Figure 2B).
L19-UG-TNFRII selectively accumulates in B-FN containing
tissues
To establish whether L19-UG-TNFRII selectively accumu-
lated on B-FN containing tissues, we ran bio-distribution
experiments using
125I radio-iodinated recombinant pro-
tein. As a model of B-FN containing tissue we use the ter-
atocarcinoma mouse model F9, since it has been
extensively evaluated for targeting of the scFv L19 and it is
possible to obtain quantitative results.
The radio-iodinated fusion protein was iv injected in
F9-tumour bearing mice; groups of 3 animals were
sacrificed at 4, 24 and 48 hours after injection.
125I-L19-UG-TNFRII showed a selective, high and very
stable accumulation in tumours. 48 hours after iv injec-
tion the %ID/g of the radio-iodinated protein in tumour
Figure 2 In vitro L19-hUG-TNFRII biological activity. A) Inhibitory activity of TNF-alpha cytotoxicity by different concentrations of L19-UG-
TNFRII using LM mouse fibroblasts treated with 2 pM TNF-alpha. B) L19-UG-TNFRII bound to ED-B is able to inhibit TNF-alpha cytotoxicity (in situ
inhibition). The cytotoxic activity of 25 pM TNF-alpha was evaluated on LM cells using plates pre-coated with the recombinant FN fragment 7.
ED-B.8.9 and pre-incubated with different concentrations of L19-UG-TNFRII (5-3125 pM). To assess the role of the L19 component the experiment
was also carried out mixing the L19-UG-TNFRII with a large excess of ED-B to inhibit of the scFv L19 moiety. After washing out the unbound
fusion protein, TNF-alpha was inhibited only by L19-UG-TNFRII bound to the recombinant FN fragment with which the plates were coated. The
means ± S.D. are reported.
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in any other organs (data not shown). Figure 3A shows
that while the %ID/g in the tumour increased with the
increase of time from the injection, the %ID/g in blood
quickly decreased. In fact, blood clearance of L19-UG-
TNFRII was mediated mainly by way of the kidneys, as
determined by evaluating urine samples, and showed a
biphasic curve with an alpha and a beta phase. Despite a
molecular size of nearly 140 KDa, the alpha and beta
phase half-life of L19-UG-TNFRII were of about 1 hour
and 20 hours respectively.
L19-UG-TNFRII reduces the signs of arthritis in the in
Collagen Antibody-Induced Arthritis (CAIA) mouse model
Arthritis was induced in mice using the Collagen Anti-
body-Induced Arthritis (CAIA) with single intravenous
injections of 2 mg of a cocktail of five anti-type II col-
lagen monoclonal antibodies. We observed evident signs
of severe arthritis in all animals on day 3, with a median
arthritis score of about 3. Figure 3B shows the therapeu-
tic results obtained by treating the animals with 50 μgo f
ip administered L19-hUG-TNFRII given daily from day
3 to day 7. Treatment with L19-UG-TNFRII was effec-
tive in improving the severity of the arthritis. We
observed improvement in the involved paws in all trea-
ted animals, with redness and swelling of the inflamed
paws being markedly reduced. On the contrary, the
severity of the disease was persistent in untreated mice.
Statistical comparison using the Mann-Whitney test
revealed highly significant differences in the scores of
treated and untreated animals showing a p < 0.03 on
day 7 and p < 0.02 on day 10 (Figure 3B).
Discussion
The ECM is essential for the normal organization and
function of all tissues and provides specific environmen-
tal signals to control cell morphology, migration, differ-
entiation, and proliferation. Thus, healthy normal tissues
that, for physiological or pathological causes, undergo
remodeling are subject to profound modifications in
ECM components in response to the mutated physiolo-
gical requirements. Indeed, at the onset and during pro-
gression of major diseases including cancer,
atherosclerosis, and rheumatoid arthritis, the ECM com-
position is altered by two main processes: proteolytic
degradation of the normal tissue’sp r e - e x i s t i n gE C M
components and neo-synthesis of new ECM compo-
nents. The interplay between these two processes results
in the generation of a provisional ECM whose compo-
nents may differ, qualitatively and quantitatively, from
their healthy counterparts. This provisional ECM pro-
vides a permissive environment for disease progression,
of which angiogenesis is a pivotal step. Thus, some dis-
ease-associated-ECM-proteins provide an attractive tar-
get for the selective delivery of drugs, and various
proteins have been investigated precisely for this pur-
pose [24].
B-FN has emerged as a prototypic component of the
provisional ECM that can be used for the selective deliv-
ery of drugs to diseased tissues. The extra domain B is a
Figure 3 In vivo L19-hUG-TNFRII bio-distribution and therapy
properties. A-B) Bio-distribution of the radio-iodinated L19-UG-
TNFRII in F9 teratocarcinoma-bearing mice. A) The %ID/g in the
tumour and in the blood at the indicated times after i.v. injection of
the radio-iodinated L19-UG-TNFRII are shown (mean ± S.D.). B) The
tumour to blood ratio of the %ID/g at different times after injection
of the radio-iodinated protein are plotted. C) In vivo therapy
experiments with L19-UG-TNFRII in CAIA animal models. The
median arthritis scores determined in treated and control mice at
day 3 to 10 from the injection of anti-collagen antibodies are
indicated. The p values determined using the non parametric Mann-
Whitney U test are indicated. Bars indicate the standard error of the
mean.
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which exon usage or skipping leads to inclusion or
exclusion of these type III repeat [6]. It is noteworthy
that the pre-mRNA alternative splicing of a number of
ECM components is cell cycle dependent and modu-
lated by cytokines and pH [25-28].
T h eE D - Bs e q u e n c ei sh i g h l yc o n s e r v e di nd i f f e r e n t
species, having 100% homology in all mammalians thus
far studied and 96% homology with a similar domain in
chicken. The use of a murine mAb, BC-1 [7], selectively
specific for B-FN, allowed immunohistochemistry stu-
dies on different tissues. Results demonstrated that B-
FN is undetectable in the tissues of healthy adults with
very rare exceptions, such as the recurrent physiological
processes of tissue remodeling and angiogenesis occur-
ring in the female reproductive system. B-FN is, in con-
trast, noticeably up regulated in foetal and tumour
tissues as well as all angiogenesis-associated diseases,
including degenerative inflammatory pathologies. Since
B-FN accumulates around new-forming vessels, it is also
an excellent marker of angiogenesis [8].
The demonstration that the mAb BC1 could be used
to selectively target tumours in vivo prompted the gen-
eration of high-affinity human recombinant antibodies
specific for the ED-B for diagnostic and therapeutic pur-
poses. In particular, the scFv L19 [29] has been investi-
gated mainly for cancer therapy, leading to preclinical
and clinical investigations of several antibody-cytokine
fusion proteins.
Here we report on the preparation of a fusion protein
composed of the scFv L19 and TNFRII. To generate a
protein that was bivalent for both L19 and TNFRII we
adopted the recently described approach using UG as a
central core of the fusion protein [16]. Human UG is a
15.8-kDa homodimeric globular non-glycosylated and
homodimeric secreted protein. The two subunits are
joined in an anti-parallel fashion by disulfide bridges
established between two highly conserved cysteine resi-
dues in the amino- and carboxyl-terminal positions. The
exact functions of UG are not yet clear, but the protein
has been reported to have anti-inflammatory properties
in view of its ability to inhibit the soluble phospholipase
A2 and tissue transglutaminase [15]. This approach
allowed the generation of a dual-specificity tetravalent
molecule using a single cDNA construct. Furthermore,
the use of UG in fusion proteins ameliorates properties
of solubility and stability [16].
To ascertain whether L19-UG-TNFRII targeted B-FN
in vivo we used the murine teratocarcinoma experimen-
tal model F9, which has been extensively studied to for-
mally demonstrate the in vivo ability of the scFv to
selectively accumulate on tissues containing B-FN.
Results demonstrate that L19-UG-TNFRII selectively
accumulates in the neoplasia and not in any of the non-
neoplastic tissues. Furthermore, we observed a very
rapid clearance from the blood, but a long residence
time in the B-FN containing tissue. The fast clearance
may reduce the toxicity of the molecules in the non-tar-
g e t e do r g a n s ,w h i l et h el o n gr e s i d e n c et i m ei nB - F N
containing tissues is useful for the therapeutic functions
of the molecule.
We have chosen a tumour model to demonstrate the
selective accumulation of L19-UG-TNFRII fusion pro-
tein on B-FN in vivo, to obtain quantitative results that
cannot be achieved using a model of RA in mice. In
fact, all the tumour mass contains B-FN it is easily and
completely removable, weighable and countable in a
gamma-counter. On the contrary, it is practically impos-
sible to selectively remove the diseased tissues in RA
models and have quantitative results such as the %ID/g.
We then carried out a study on the therapeutic activ-
ity of the L19-UG-TNFRII using the CAIA mouse
model. Although the clearance was very fast compared
to the half-life of about 100 hrs of etanercept, we
observed very significant results in the reduction of
rheumatoid arthritis symptoms. This could be due to
the selective accumulation of TNFRII in the hypervascu-
larized arthritic joints containing high quantities of B-
FN.
We realize that much more extensive preclinical stu-
dies are needed, in particular comparative studies
between targeted and non-targeted TNFRII, as well as
combination studies using non-targeted TNFRII to neu-
tralize blood TNF-alpha and L19-UG-TNFRII to neutra-
lize tissue TNF-alpha; this combination should allow
reduction of the total amount of administered TNFRII,
thereby leading to a reduction of side effects. The anti-
inflammatory potential of the UG component in the
fusion protein must also be evaluated, and this should
be possible using the fusion protein L19-UG that we
have recently described [16]. The therapeutic efficacy of
the targeted delivery of TNF-alpha antagonists to the
inflamed tissues may thus provide a fertile future
research area and yield important contributions for the
therapy of degenerative inflammatory diseases.
Conclusion
Using UG as a scaffold and the FN isoform containing
the ED-B as a target, we have generated a fusion pro-
tein (L19-UG-TNFRII) able to selectively deliver a
TNF-alpha inhibitor to inflamed tissues and we
demonstrated that this fusion protein was able to sig-
nificantly improve the severe symptomatology of
arthritis in collagen antibody-induced arthritis (CAIA)
mouse model.
Furthermore using this platform, an antibody specific
for a component of the ECM of inflamed tissues, UG as
a scaffold and an anti-inflammatory molecule as effector,
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could yield important contributions for the therapy of
degenerative inflammatory diseases.
Methods
Preparation of cDNA construct, expression, purification
and characterization of L19-hUG-TNFRII
The cDNA encoding for L19 fused to human UG and to
the extracellular ligand-binding portion of the human 75
KDa (p75) tumour necrosis factor receptor (TNFRII),
optimized for expression in Chinese hamster ovary
(CHO) cells and cloned into pcDNA3.1 mammalian
expression vector (Invitrogen, Carlsbad, CA, USA), was
provided by Genscript Corporation (Piscataway, NJ,
USA).
The cDNA construct was used to transfect mamma-
lian CHO cells (American Tis s u eT y p eC u l t u r eC o l l e c -
tion, Manassas, VA) with the use of Lipofectamine 2000
CD Reagent (Invitrogen) according to the manufac-
turer’s instructions. Cells were grown in RPMI 1640
(Sigma-Aldrich, St Louis, MO, USA) supplemented with
10% foetal bovine serum (Sigma) and 4 mM L-gluta-
mine (Invitrogen).
L19-UG-TNFRII was purified from the spent media of
the transfected cells by immunoaffinity chromatography
on the recombinant extra-domain B (ED-B) fragment of
FN [30] conjugated to Sepharose 4B (GE Healthcare,
Uppsala, Sweden).
The purified protein was analysed by sodium dodecyl
sulfate-plyacrylamide gel electrophoresis (SDS-PAGE;
4%-12%) under reducing and non-reducing conditions
and in native conditions by fast-protein liquid chroma-
tography (FPLC) on a S200 chromatography column.
The biological activity in vitro of the recombinant pro-
tein was assessed by determining the inhibition of
human TNF-alpha cytotoxicity on mouse L-M fibro-
blasts (ATCC) as previously described [16].
Radio-iodination and bio-distribution experiments of L19-
UG-TNFRII
L19-UG-TNFRII was radio-iodinated as previously
described [24] using the Iodogen method (Pierce, Rock-
ford, IL, USA). 129/SvHsd mice (Harlan Italy, Udine,
Italy) with subcutaneously implanted 3 × 10
6 F9 murine
syngenic teratocarcinoma cells, were injected intrave-
nously with roughly 5 μg( 6 , 4μCi, 0,237 MBq) of pro-
tein in 100 μl saline solution. Mice were sacrificed at 4,
24 and 48 hr after injection. The organs and the tumour
were weighed and the radioactivity was counted in a
gamma counter. Targeting results are expressed as a
percent of the injected dose per gram of tissue (%ID/g).
Housing, treatment and sacrifice of animals complied
with national legislative provisions (Italian law no. 116
of 27 January, 1992).
In vivo experiments in Collagen Antibody-Induced
Arthritis (CAIA) models
Adult male DBA/1J mice were purchased from Harlan
(Oxon UK). Arthritis was indu c e db yas i n g l ei n t r a v e -
nous injection of 2 mg of Arthrogen-CIA Arthritogenic
Monoclonal Antibody Cocktail (Chondrex, Redmond,
WA, USA) on day 0. On day 3, animals were randomly
divided into two groups of six animals each; the first
group received daily intraperitoneal injections of 50 μg
of L19-UG-TNFRII dissolved in 20 mM sodium-phos-
phate buffer pH 7.6 containing 0.15 M NaCl. Animals
were treated from day 3 to day 7. The second set of ani-
mals was used as untreated control group.
Animals were weighed daily and monitored for the
onset and progression of disease from day 0 to day 10.
Paws were assigned a clinical score between 0 and 4
according to the index: 0 = no arthritis; 1 = mild invol-
v e m e n ti nas i n g l ea r e a( s i n g l ei n t e r p h a l a n g e a lj o i n t ,
mid-foot or wrist/ankle); 2 = moderate/severe involve-
ment in a single area (as above) or mild involvement in
2-3 areas; 3 = severe involvement in two areas or mod-
erate involvement in several areas; 4 = severe involve-
ment in all areas. Statistical significance was determined
using the non parametric Mann-Whitney U test. Differ-
ences were considered significant when p < 0.05. Haus-
ing treatment, and killing of the animals were carried
out in Genoa (Italy) at The National Cancer Research
Institute’s animal facility (authorization of the Italian
Ministry of Health no.146/2009-A) and followed
national legislative provisions (Italian low no.116 of Jan-
uary 1992). The project (no. 299) regarding the studies
reported in this manuscript was approved by the Ethical
Committee for studies on animals and by the Italian
Ministry of Health.
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